Prevention of Bronchopulmonary Dysplasia: A Summary of Evidence-Based Strategies

Erik A. Jensen, MD, MSCE*

*Division of Neonatology and Department of Pediatrics; Children's Hospital of Philadelphia and University of Pennsylvania, Philadelphia, PA

Education Gap

To decrease rates of bronchopulmonary dysplasia among extremely preterm infants, clinicians must implement multiple evidence-based strategies that target disease prevention. Less invasive surfactant administration is an emerging therapy that may help prevent bronchopulmonary dysplasia.

Abstract

Bronchopulmonary dysplasia (BPD) is the most common chronic complication associated with extremely preterm birth. Although BPD is now an uncommon condition in infants born with birthweights higher than 1,500 g, among infants born at or near the current limits of viability, BPD rates have not improved over the past 2 to 3 decades and may be increasing. No single therapeutic intervention is effective at preventing BPD. As such, clinicians must use multiple evidence-based strategies to help reduce BPD rates. This review examines current evidence-based approaches to BPD prevention, primarily focusing on data obtained from randomized controlled trials.

Objectives   After completing this article, readers should be able to:

1. Describe current evidence-based therapies shown in randomized controlled trials to reduce bronchopulmonary dysplasia risk among very preterm infants.

2. Become familiar with the data available on the safety and efficacy of corticosteroids for preventing bronchopulmonary dysplasia in extremely preterm infants and explain the current limitations in knowledge about the optimal timing, dosing regimen, and patient selection for treatment.

ABBREVIATIONS

BPD	bronchopulmonary dysplasia
CI	confidence interval
CP	cerebral palsy
CPAP	continuous positive airway pressure
HFNC	high-flow nasal cannula
HFOV	high-frequency oscillatory ventilation
INSURE	intubation, surfactant administration during brief mechanical ventilation followed by extubation
LISA	less invasive surfactant administration
NEC	necrotizing enterocolitis
NIPPV	nasal intermittent positive pressure ventilation
OR	odds ratio
PDA	patent ductus arteriosus
RCT	randomized controlled trial
RDS	respiratory distress syndrome
RR	relative risk

INTRODUCTION

Bronchopulmonary dysplasia (BPD) is one of the most common complications of preterm birth. It affects approximately half of all infants born with birthweights less than 1,000 g, is associated with increased risk for early childhood mortality, and predisposes survivors to chronic respiratory and cardiovascular impairments,

growth failure, and neurodevelopmental delay. (1)(2)(3)(4)(5)(6)(7) BPD was once a frequent problem among all preterm infants treated with prolonged invasive mechanical ventilation. With increased use of antenatal corticosteroids, surfactant therapy, and gentle ventilation strategies, BPD is now uncommon in preterm infants born with birthweights greater than 1,500 g. (8) However, most of the data available suggest that BPD rates have not improved in recent decades among extremely preterm infants and may be increasing. (7)(8)(9)(10) One hindrance to preventing BPD in this population is the lack of a safe and highly efficacious preventive therapy. As such, clinicians must use multiple evidence-based strategies to reduce BPD risk. This review discusses the evidence supporting currently available therapies for BPD prevention in very preterm infants, primarily focusing on data obtained from randomized controlled trials (RCTs).

RESPIRATORY SUPPORT STRATEGIES

Successful transition to postnatal breathing requires clearance of fetal lung fluid and lung aeration. The high chest wall compliance, weak respiratory muscles, incomplete surfactant production, and underexpression of transepithelial sodium channels in very preterm infants hinder this process. (11)(12)(13)(14) As a result, many very preterm infants require positive airway pressure and supplemental

oxygen soon after birth to maintain physiologic stability. Invasive mechanical ventilation can be lifesaving in these instances, but it may also lead to lung injury. Animal data show a clear link between baro- and volutrauma induced by mechanical ventilation and pathologic changes in the lung that mimic BPD. (15)(16) Moreover, observational studies support an association between invasive mechanical ventilation and increased BPD risk. (17)(18) To help minimize lung injury and prevent BPD, investigators have explored several different noninvasive and "gentler" invasive ventilation strategies. Salient results from these efforts are described herein; data from RCTs showing benefit for BPD prevention are summarized in Fig 1.

Noninvasive Positive Airway Pressure
One strategy to prevent ventilator-induced lung injury is to avoid mechanical ventilation altogether. Three large RCTs compared early noninvasive continuous positive airway pressure (CPAP) with immediate intubation and surfactant administration. (19)(20)(21) Although design elements, including gestational ages of the enrolled infants and initial CPAP settings (ranging from 5–8 cm H_2O) varied among the studies, each demonstrated a nonsignificant reduction in the rate of death or BPD at 36 weeks' postmenstural age among the infants initially treated with CPAP. (19)(20)(21) Meta-analyses of the available trial data, some of which also

Intervention	Outcome	Trials / N	Outcome Rates Intervention	Outcome Rates Control	Relative Risk (95% CI)		Number Needed to Treat to Benefit (95% CI)	
Respiratory Support Strategies								
nCPAP vs. MV[23]	Death or BPD	4 / 2782	40%	43%	0.90 (0.83-0.98)	◆	25 (13-244)	
sNIPPV vs. nCPAP after extubation[29]	BPD	3 / 181	28%	43%	0.64 (0.44-0.95)	◆	7 (4-42)	
Volume-targeted vs. pressure-limited MV[31]	BPD among survivors	9 / 620	23%	35%	0.68 (0.53-0.87)	◆	9 (6-24)	
HFOV vs. pressure-limited MV[32]	BPD among survivors	17 / 2786	30%	35%	0.86 (0.78-0.96)	◆	21 (13-66)	
	Death or BPD	17 / 3329	41%	45%	0.90 (0.84-0.97)	◆	22 (13-69)	
Surfactant Administration								
Surfactant ≤ 2hr vs. > 2hr of age + MV[38]	BPD	3 / 3050	8%	11%	0.69 (0.55-0.87)	◆	29 (18-74)	
	Death or BPD	3 / 3050	29%	35%	0.83 (0.75-0.91)	◆	16 (11-34)	
LISA vs. INSURE[52]	Death or BPD	3 / 426	15%	23%	0.63 (0.42-0.93)	◆	12 (6-66)	

0.4   0.6   0.8   1   1.2   1   3   10   50   200

Favors Intervention   Favors Control

Figure 1. Summary of randomized, controlled trial data on the effects of various respiratory support strategies for preventing death and/or bronchopulmonary dysplasia. Study results are abstracted from the cited publication when available. If not provided in the article, relative risk and number needed to treat to benefit values (inverse of the risk difference) were calculated using original study data in RevMan version 5.3 (the Nordic Cochrane Centre, Copenhagen, Denmark). BPD=bronchopulmonary dysplasia; CI=confidence interval; HFOV=high-frequency oscillatory ventilation; INSURE=*in*tubation, *sur*factant administration during brief mechanical ventilation, followed by *e*xtubation; LISA=less invasive surfactant administration; MV=mechanical ventilation; N=total number of infants evaluated for the outcome; nCPAP=nasal continuous positive airway pressure; sNIPPV=synchronized nasal intermittent positive pressure ventilation.

included smaller RCTs, showed a small but statistically significant reduction in the risk for death or BPD with CPAP therapy (Fig 1). (22)(23)(24) Although one large trial reported higher rates of pneumothorax in CPAP-treated infants, (20) meta-analyses did not show an increased risk for pneumothorax or other adverse events with early CPAP. (22)(23)(24) As a result, the American Academy of Pediatrics Committee on Fetus and Newborn recommends early use of CPAP with subsequent selective surfactant administration in extremely preterm infants as an evidence-based strategy to reduce the risk for death or BPD. (25)

Heated and humidified high-flow nasal cannula (HFNC), typically administered with flow rates higher than 1 to 2 L/min, has gained popularity as an alternative to nasal CPAP. Potential advantages of HFNC include reduced nasal trauma, simpler device setup, and greater facilitation of oral feeding and skin-to-skin care. (26) However, recent trial data indicate that HFNC and nasal CPAP may not be equivalent therapies. Treatment failure is more common among very preterm infants who receive HFNC compared with nasal CPAP as a primary support modality. (26) HFNC may be an acceptable alternative to nasal CPAP for postextubation support among infants born at more than or equal to 28 weeks of gestation, but routine use in less mature infants is not recommended. (27)

Nasal intermittent positive pressure ventilation (NIPPV) augments nasal CPAP by providing brief periods of higher airway pressure, synchronized with an infant's breathing or delivered at set, asynchronous intervals. Use of NIPPV in preterm infants as an initial mode of respiratory support or after extubation from mechanical ventilation, when compared with CPAP, results in improved short-term respiratory outcomes without an increased risk of harm. (28)(29) Despite this benefit, meta-analyses do not show a reduction in BPD with NIPPV. (28)(29) Synchronized NIPPV, particularly when used after extubation, may reduce BPD risk (Fig 1), but further research into the usefulness of this specific form of noninvasive support is needed. (29)

Mode of Invasive Mechanical Ventilation

Not all very preterm infants safely transition to postnatal breathing with noninvasive respiratory support. Data from CPAP trials indicate that up to 65% of spontaneously breathing extremely preterm infants require intubation and mechanical ventilation despite early CPAP therapy. (23) In these instances, or when invasive respiratory support is required soon after birth, clinicians must select a mode of mechanical ventilation. Trauma to the developing lung from excessive volumetric stretch is one proposed contributor to the development of BPD. (30) Owing to rapid changes in

lung compliance in the first days and weeks after birth, volume-targeted ventilation in very preterm infants may be optimal. A 2017 Cochrane review found moderate quality of evidence supporting the use of volume-targeted ventilation as opposed to pressure-limited ventilation as a means to reduce the composite outcome of death or BPD, length of mechanical ventilation, and rates of severe intraventricular hemorrhage (Fig 1). (31)

High-frequency oscillatory ventilation (HFOV) is an alternative ventilation strategy that may reduce lung injury. A 2015 Cochrane review evaluating HFOV as a primary mode of invasive respiratory support (ie, not as a rescue therapy after "failed" conventional mechanical ventilation) found a small reduction in the risk for death or BPD and BPD alone among infants treated with HFOV compared with pressure-limited conventional ventilation (Fig 1). (32) Pulmonary air leaks (pneumothorax or pulmonary interstitial emphysema) were more common in HFOV-treated infants. (32) Ultimately, the authors concluded that the "preference for a specific ventilation mode remains a matter of clinical judgment requiring a balance between a relatively small benefit and a possible short-term harm." (32)

SURFACTANT

Endotracheal Surfactant Administration Followed by Mechanical Ventilation

Endogenous pulmonary surfactant is a mixture of lipids and proteins that primarily act to reduce surface tension at the air/liquid interface within the alveoli and improve deflation stability of the lungs. (33) Deficiency of pulmonary surfactant in extremely preterm infants is a key component in the pathophysiology of neonatal respiratory distress syndrome (RDS). (34) Several older RCTs, conducted before the routine use of antenatal corticosteroid and early noninvasive CPAP, showed that administration of exogenous surfactant, compared with mechanical ventilation alone, reduced rates of death or supplemental oxygen use 28 days after delivery (the standard definition of BPD at that time). (35)(36)(37) As described herein, use of noninvasive respiratory support as a primary modality is the preferred approach for most very preterm infants. However, these older trial data support the use of exogenous surfactant in very preterm infants who require intubation and mechanical ventilation within the first 48 to 72 hours of age. In these instances, early treatment with surfactant may be optimal. Rescue surfactant administration to preterm infants receiving mechanical ventilation within the first 2 hours of age, compared with after the second hour of age, reduces the risk for BPD and the composite risk for death or BPD (Fig 1). (38)

There are several commercially available surfactant formulations available for use. The animal-derived preparations (modified or purified from bovine or porcine lungs) provide a small benefit for reductions in rates of mortality and death or BPD compared with first-generation protein free surfactants. (39) Meta-analysis of trials comparing modified bovine-derived surfactant to porcine-based surfactant suggested that bovine products may increase mortality and BPD risk. (40) However, subgroup analyses suggested that these differences were limited to trials using a higher initial dose of porcine-derived surfactant and may not be due to the animal source. (40) Lucinactant, a second-generation synthetic surfactant that contains a peptide analog of surfactant protein B, has similar efficacy as animal-derived products. (41)(42)

Surfactant Administration without Prolonged Mechanical Ventilation

To maximize the potential benefits of early surfactant administration without the harmful effects of prolonged invasive mechanical ventilation, investigators explored alternative means to dosing surfactant. Victorin et al introduced the technique of *in*tubation, *sur*factant administration during brief mechanical ventilation, followed by *e*xtubation (INSURE). (43) Although initial RCTs found that INSURE reduced supplemental oxygen use at 28 days of age, meta-analyses including more recent trials found that compared with CPAP, INSURE does not reduce the risk for death or BPD (relative risk [RR] 0.88, 95% confidence interval [CI] 0.76–1.02). (44)(45)

Several techniques have been developed for less invasive administration of surfactant to avoid standard endotracheal intubation. These include intratracheal instillation of surfactant with a thin catheter (eg, nasogastric tube), aerosolized surfactant, intrapartum pharyngeal instillation, and delivery via a laryngeal mask airway. (46) Of these strategies, surfactant instillation via a thin catheter, typically referred to as less invasive surfactant administration (LISA) or minimally invasive surfactant therapy, is the most studied. Four RCTs conducted in extremely preterm infants compared LISA with endotracheal tube administration of surfactant (3 versus INSURE, 1 versus continued mechanical ventilation after surfactant therapy), (47)(48)(49)(50) and 1 compared LISA with CPAP therapy alone. (51) A meta-analysis combining data from these RCTs showed that LISA versus control therapy reduced the risk for BPD among survivors (RR 0.70, 95% CI 0.50–0.97) and the composite of death or BPD (RR 0.74, 95% CI 0.58–0.94). (52) Compared with INSURE alone, LISA reduced the risk for death or BPD (Fig 1) but not BPD among survivors (RR 0.65, 95% CI 0.35–1.19). (52)

Isayama et al conducted a recent Bayesian network meta-analysis comparing 6 early respiratory strategies (mechanical ventilation, nasal CPAP, noninvasive positive pressure ventilation, INSURE, LISA, and nebulized surfactant administered via laryngeal mask airway). (53) This approach estimated the relative effects of each intervention, even if they were not compared in individual trials. The analysis showed that LISA was associated with the largest reduction in the risk for death or BPD (odds ratio [OR] 0.49, 95% CI 0.30–0.79). (53) However, the authors noted that the findings were limited by the overall low quality of evidence. (53) A large, ongoing trial evaluating LISA in extremely preterm infants will provide important data on this method of surfactant administration. (54)

PHARMACOLOGIC THERAPIES

Despite the strong physiologic and observational data implementing invasive mechanical ventilation in the development of BPD, the beneficial effects of the respiratory support strategies described herein are modest. Longitudinal data also suggest that increased use of noninvasive respiratory support over time has not been accompanied by substantial improvements in BPD rates or childhood lung function among surviving extremely preterm infants. (55) Owing to the limited benefit of gentle ventilation techniques, pharmacologic therapies are an essential component in ongoing efforts to reduce BPD rates. Drug therapies shown in RCTs to reduce BPD are summarized herein and in Fig 2.

Noncorticosteroid Agents

Azithromycin. Azithromycin is a macrolide antibiotic that exhibits both antimicrobial and anti-inflammatory properties. (56)(57) These dual qualities make it a potentially appealing mode of BPD prevention. In very preterm infants, infection with *Ureaplasma* is associated with the development of BPD. (58)(59) Moreover, lung and systemic inflammation contribute to BPD pathophysiology. (60)(61) Three small trials assessed the efficacy of azithromycin in preventing BPD. (62) A meta-analysis of these studies found a reduction in the risk for BPD and death or BPD alone among infants treated with azithromycin (Fig 2), regardless of known *Ureaplasma* colonization or infection. (62) However, none of the individual studies demonstrated benefit, and the quality of evidence was low. (62)(63) Finally, trials evaluating other macrolides have not shown benefit for preventing BPD. (64)(65) Larger trials are needed to establish safety and efficacy of prophylactic azithromycin before recommending this therapy. (63)

Medication	Outcome	Trials / N	Outcome Rates		Relative Risk (95% CI)	Number Needed to Treat to Benefit (95% CI)
			Treatment	Control		
Non-corticosteroids						
Azithromycin	BPD among survivors	3 / 310	50%	60%	0.83 (0.71-0.97)	10 (5-56)
	Death or BPD	3 / 363	57%	67%	0.86 (0.77-0.97)	11 (6-55)
Caffeine	BPD among survivors	1 / 1917	36%	47%	0.78 (0.70-0.86)	10 (7-16)
Vitamin A (IM)	BPD among survivors	4 / 886	43%	50%	0.85 (0.74-0.98)	13 (7-97)
Corticosteroids						
Dexamethasone (< 8 days of life)	BPD among survivors	14 / 1917	26%	36%	0.73 (0.64-0.83)	10 (7-17)
	Death or BPD	16 / 2581	44%	51%	0.87 (0.80-0.94)	15 (10-32)
Dexamethasone (> 7 days of life)	BPD among survivors	6 / 259	56%	73%	0.78 (0.66-0.92)	6 (4-16)
	Death or BPD	10 / 516	56%	77%	0.73 (0.65-0.83)	5 (4-8)
Hydrocortisone (24 hours of life)	Death or BPD	1 / 523	40%	49%	0.82 (0.67-0.99)	11 (6-268)
Hydrocortisone (< 8 days of life)	Death or BPD	9 / 1379	52%	58%	0.90 (0.82-0.99)	17 (9-132)
Budesonide (inhaled)	BPD among survivors	3 / 776	28%	38%	0.74 (0.60-0.90)	10 (6-27)
Budesonide + Surfactant (intratracheal)	BPD	2 / 381	25%	44%	0.57 (0.43-0.76)	5 (4-10)
	Death or BPD	2 / 381	39%	65%	0.60 (0.49-0.74)	4 (3-6)

Relative Risk axis: 0.4 0.6 0.8 1 1.2 — Favors Treatment / Favors Control

Number Needed to Treat axis: 1 3 10 50 200

Figure 2. Summary of randomized, controlled trial data on the effects of various medications for preventing death and/or bronchopulmonary dysplasia. Study results are abstracted from the cited publication when available. If not provided in the article, relative risk and number needed to treat to benefit values (inverse of the risk difference) were calculated using original study data in RevMan version 5.3 (the Nordic Cochrane Centre, Copenhagen, Denmark). BPD=bronchopulmonary dysplasia; CI=confidence interval; IM=intramuscular.

Caffeine. Caffeine is approved by the US Food and Drug Administration for the treatment of neonatal apnea among infants born with gestational ages from 28 weeks to less than 33 weeks. The Caffeine for Apnea of Prematurity trial showed that caffeine also reduced BPD risk among infants with birthweights of 500 to 1,250 g and improved neurodevelopmental outcomes at 18 to 21 months' corrected age (Fig 2). [66][67] Follow-up trial data collected through age 11 years indicated that caffeine resulted in durable, long-term improvement in motor function. [68] Recent neonatal studies showed that beginning caffeine therapy within the first 72 hours of age may result in the greatest reduction in BPD risk. [69][70][71][72][73] Importantly, it is uncertain whether these findings are indicative of a true benefit of early caffeine or greater illness severity among the infants treated with caffeine beginning at later ages. Although further studies are needed to evaluate the risks and benefits of very early caffeine therapy, particularly among extremely preterm infants receiving invasive mechanical ventilation, use of caffeine soon after birth in most extremely preterm infants is recommended. [63]

Vitamin A. Vitamin A is required for the growth and maturation of epithelial cells lining the respiratory tract. [74][75] Earlier studies showed that preterm infants who developed BPD, compared with those who did not, had lower plasma vitamin A levels. [76][77][78] Subsequently, a large, multicenter trial published in 1999 found that intramuscular injections of vitamin A during the first 4 weeks of age reduced rates of death or BPD and BPD alone among surviving extremely low-birthweight infants. [79] Meta-analysis of all trial data confirmed a small benefit for reducing BPD among survivors (Fig 2) but not for the composite outcome of death or BPD (RR 0.90, 95% CI 0.81–1.01). [80] More recent observational studies call into question the true effectiveness of vitamin A in the current era. One large study showed similar rates of BPD among infants who received vitamin A and untreated controls whereas another found that BPD rates remained stable during a vitamin A shortage in the United States, despite a precipitous drop in use of the supplement. [81][82] An ongoing RCT investigating enteral vitamin A may help resolve the conflict between the trial and observational data. [83] However, in

the absence of these results, intramuscular vitamin A is recommended, if commercially available, as an evidence-based strategy to prevent BPD in extremely preterm infants.

Corticosteroids

The potent anti-inflammatory properties of corticosteroids make them a logical therapeutic agent for BPD prevention. Unfortunately, the potential for long-term harm with corticosteroids and deficiencies in the available trial data, including variability in study design and frequent open-label steroid use among randomized infants, hinder the ability to determine the true risks and benefits of postnatal corticosteroids in very preterm infants.

Dexamethasone (Systemic). Of all corticosteroids, the use of dexamethasone to prevent BPD has been studied in the largest number of RCTs. Owing to differences in risk profile, meta-analyses incorporating these trials typically group studies evaluating dexamethasone initiated within the first 8 days of age ("early use") separately from those initiating therapy after this time point ("late use"). The most recent Cochrane review on early dexamethasone therapy found that although use within the first 8 days after birth reduced BPD risk (Fig 2), it increased the risks for gastrointestinal perforation, hypertrophic cardiomyopathy, cerebral palsy (CP), and major neurosensory disability. (84) Because of these unacceptable side effects, early dexamethasone for BPD prevention is not recommended.

The risks and benefits of "late" dexamethasone are less well-established. Meta-analysis of the available trial data shows that initiation of dexamethasone after the first week of age reduces BPD risk (Fig 2), but carries the short-term side effects of hyperglycemia, glycosuria, and hypertension. (85) In contrast to early use, a recent meta-analysis did not find clear evidence of increased CP risk among surviving infants treated with late dexamethasone. (85) However, none of the follow-up studies were adequately powered to evaluate long-term outcomes, and the high rates of open-label dexamethasone use in these studies may mask actual treatment effects. (85)(86)

Ultimately, clinicians considering whether to administer "late" dexamethasone to individual infants must balance the medication's beneficial respiratory effects with the potential adverse effects on long-term neurodevelopment. An important component in this calculus is the recognition that BPD is itself a risk factor for poor neurologic outcomes. (87)(88) A meta-regression conducted by Doyle et al provides the best means for clinicians to balance these competing risks. (88) This study showed that when the risk for BPD in the control population (akin to an infant's baseline BPD risk) was less than 33%, corticosteroids significantly increased the risk for death or CP. (88)

Alternatively, when the risk for BPD exceeded 60%, corticosteroids reduced death or CP risk. (88) Therefore, in infants at low to moderate risk for BPD, the adverse long-term effects of dexamethasone likely outweigh the benefits. Conversely, among infants at high risk, the balance may favor dexamethasone therapy.

If a clinician decides to administer dexamethasone, he/she must then select a dose and treatment duration. Although general consensus favors the use of low, tapering doses administered for short periods (1–2 weeks at most), robust data to guide these specific choices are limited. (89) The dosing regimen used in the discontinued Dexamethasone: A Randomized Trial (DART) study (0.89 mg/kg administered over 10 days) is one such approach. (90) In this trial of 70 very preterm infants receiving invasive mechanical ventilation, compared with placebo, dexamethasone significantly improved rates of successful extubation (dexamethasone group 60%, placebo group 12%) without evidence of long-term harm. (90)(91) However, the risk for BPD was not significantly reduced in the dexamethasone-treated infants (OR 0.58, 95% CI 0.13–2.66). (90)

Hydrocortisone (Systemic). To date, 9 trials have evaluated the safety and efficacy of systemic hydrocortisone initiated in the first week after birth for prevention of death or BPD. (84) The largest of these studies, the PREMILOC trial, compared a 10-day course of low-dose hydrocortisone initiated within the first 24 hours after birth with placebo in infants born at less than 28 weeks' gestation. (92) Rates of survival without BPD were higher among the hydrocortisone-treated infants (Fig 2). (92) However, a subgroup analysis demonstrated a nearly 2-fold increase in the risk for late-onset sepsis among infants born at 24 to 25 weeks' gestation treated with early hydrocortisone. (92) Hydrocortisone also did not improve 2-year neurodevelopmental outcomes despite a reduction in death or BPD. (93) Meta-analysis of all available trials initiating hydrocortisone in the first week of age showed a reduction in the composite outcome of death or BPD with hydrocortisone therapy (Fig 2) but no benefit for BPD among survivors. (84) Gastrointestinal perforation was more common in the hydrocortisone-treated infants. (84) A recently completed RCT conducted in the US Neonatal Research Network evaluating the safety and efficacy of hydrocortisone administered to preterm infants receiving invasive mechanical ventilation at 14 to 28 days will provide additional safety and efficacy data.

Budesonide (Inhaled). Inhaled corticosteroids offer the potential benefit of reducing inflammation in the lung without the adverse side effects of systemically administered corticosteroids. The efficacy of 4 different inhaled steroids (budesonide, beclamethasone, fluticasone, flunisolide) for preventing BPD has been studied in RCTs. (94)(95)

A meta-analysis of all trial data (inclusive of all 4 steroids) demonstrated a reduced BPD risk among surviving infants (RR 0.76, 95% CI 0.63–0.93) and the composite outcome of death or BPD (RR 0.86, 95% CI 0.75–0.99) among infants treated with inhaled corticosteroids. (94) These beneficial findings are primarily driven by the multicenter NEUROSIS trial, which found that inhaled budesonide decreased rates of BPD among survivors (Fig 2), but at the expense of greater mortality among budesonide-treated infants. (96)(97) Rates of neurodevelopmental impairment at 18 to 22 months' corrected age were similar between the 2 study groups. (97) Although no etiology has been identified for the higher mortality in the budesonide group, this concerning finding outweighs the observed benefit for BPD. (97)

Two RCTs evaluated the usefulness of intratracheal budesonide combined with surfactant relative to surfactant therapy alone among very-low-birthweight infants with severe RDS. (98) The combined therapy reduced the risk for death or BPD (Fig 2). (98) Follow-up performed up to 3 years of age found no difference in motor or cognitive function between the groups. (98) This promising finding awaits confirmation in larger trials before widespread use is recommended.

INEFFECTIVE OR UNPROVEN THERAPIES FOR BPD PREVENTION

Multiple medications and care strategies that are potentially useful for BPD prevention have ultimately been shown in RCTs to not reduce BPD risk. Although review of each of these therapies is outside the scope of this article, a few of the more common strategies warrant discussion.

Antenatal Corticosteroids
Administration of antenatal corticosteroids to pregnant women at 23 to 33 6/7 weeks' gestation who are at increased risk for preterm delivery within the subsequent week is an evidence-based strategy to reduce neonatal morbidity and mortality. Meta-analysis of available trial data indicate that premature infants of women treated with antenatal steroids are at significantly reduced risk for developing neonatal RDS, intraventricular hemorrhage, necrotizing enterocolitis (NEC), and early-onset sepsis. (99) Despite these benefits, antenatal steroids have not been shown to reduce the risk for BPD in RCTs (RR 0.86, 95% CI 0.42–1.79) or large observational studies. (99)(100)

Treatment of a Patent Ductus Arteriosus
Observational data demonstrate a strong association between the presence of a patent ductus arteriosus (PDA) and the development of BPD. (101)(102) Despite this evidence, no medication that targets ductal closure (indomethacin, ibuprofen, acetaminophen) administered prophylactically or after identification of a "hemodynamically significant" PDA has been shown to reduce BPD risk. (103)(104)(105)(106)(107) Surgical ligation effectively achieves closure of the PDA, but may increase the risk for BPD and long-term neurodevelopmental impairment. (108)(109) Although it is possible that some very preterm infants may benefit from medical or interventional closure of the PDA, there are no evidence-based strategies to reliably identify these infants and then select the optimal therapeutic approach.

Fluid Restriction and Diuretics
Excessive fluid intake may result in pulmonary edema and need for greater respiratory support. Observational data indicate that extremely low-birthweight infants who receive higher fluid intake and those with less robust weight loss in the first 1 to 2 weeks of age more commonly develop BPD. (102) However, the limited trial data do not show clear benefit with restrictive versus more liberal fluid administration. (110) Diuretics may reduce pulmonary edema and provide short-term improvement in respiratory mechanics in preterm infants but there are no data indicating reduced BPD risk with regular diuretic use. (111)

Inhaled Nitric Oxide
Inhaled nitric oxide is a potent pulmonary vasodilator and an effective treatment for persistent pulmonary hypertension in near-term and full-term newborns. (112) Despite these benefits, inhaled nitric oxide does not prevent BPD when used as an early routine strategy or as a rescue therapy in very preterm infants. (113)(114) A recent individual patient meta-analysis using data from a subset of trials suggested that inhaled nitric oxide may reduce BPD risk among black preterm infants. (115) This promising finding requires validation in future studies.

Breast Milk
Mother's own milk is the preferred source of enteral nutrition for most very preterm infants. In addition to being associated with reduced risk of developing NEC and late-onset sepsis, observational studies suggest that preterm infants who receive an exclusive diet of the mother's own milk as compared to preterm formula are less likely to develop BPD. (116)(117) Donor human milk is gaining popularity as an alternative to preterm formula when the mother's own milk is not available. Although the current trial data indicate that donor human milk reduces the risk

for NEC, it does not lower BPD risk or improve long-term neurodevelopmental outcomes. (118)

CONCLUSION

BPD remains the most common chronic complication associated with extremely preterm birth. Strategies to minimize lung injury and prevent BPD must begin in the immediate perinatal period and likely continue throughout hospitalization. Initial respiratory care of very preterm infants should begin with nasal CPAP, with endotracheal intubation and surfactant administration reserved for those who fail noninvasive support or do not demonstrate spontaneous respiratory effort after resuscitation. For infants receiving invasive mechanical ventilation, use of a volume-targeted approach rather than pressure-limited ventilation may reduce BPD risk. Caffeine and vitamin A are the only medications with high-quality evidence to support routine use for BPD prevention. Dexamethasone is an effective therapy, but for many infants, the risks for adverse effects with this medication outweigh the benefits. However, for those at high risk of developing BPD, dexamethasone initiated after the first week of age may be appropriate. Hydrocortisone is an alternative option that has been shown in RCTs to reduce rates of death or BPD when initiated in the first week of age. Unfortunately, this benefit may come at the expense of higher rates of sepsis and gastrointestinal perforation without advantages for long-term neurodevelopment. Less invasive surfactant administration is a promising intervention currently under investigation.

American Board of Pediatrics Neonatal-Perinatal Content Specification

- Be aware of various preventive strategies for bronchopulmonary dysplasia/chronic lung disease.

References

1. Berkelhamer SK, Mestan KK, Steinhorn RH. Pulmonary hypertension in bronchopulmonary dysplasia. *Semin Perinatol.* 2013;37(2):124–131

2. Bott L, Béghin L, Devos P, Pierrat V, Matran R, Gottrand F. Nutritional status at 2 years in former infants with bronchopulmonary dysplasia influences nutrition and pulmonary outcomes during childhood. *Pediatr Res.* 2006;60(3):340–344

3. Carraro S, Filippone M, Da Dalt L, et al. Bronchopulmonary dysplasia: the earliest and perhaps the longest lasting obstructive lung disease in humans. *Early Hum Dev.* 2013;89(Suppl 3):S3–S5

4. Cristea AI, Carroll AE, Davis SD, Swigonski NL, Ackerman VL. Outcomes of children with severe bronchopulmonary dysplasia who were ventilator dependent at home. *Pediatrics.* 2013;132(3):e727–e734

5. Doyle LW, Faber B, Callanan C, Freezer N, Ford GW, Davis NM. Bronchopulmonary dysplasia in very low birth weight subjects and lung function in late adolescence. *Pediatrics.* 2006;118(1):108–113

6. Ehrenkranz RA, Walsh MC, Vohr BR, et al; National Institutes of Child Health and Human Development Neonatal Research Network. Validation of the National Institutes of Health consensus definition of bronchopulmonary dysplasia. *Pediatrics.* 2005;116(6):1353–1360

7. Stoll BJ, Hansen NI, Bell EF, et al; Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network. Trends in care practices, morbidity, and mortality of extremely preterm neonates, 1993-2012. *JAMA.* 2015;314(10):1039–1051

8. Bancalari E, Claure N, Sosenko IRS. Bronchopulmonary dysplasia: changes in pathogenesis, epidemiology and definition. *Semin Neonatol.* 2003;8(1):63–71

9. Botet F, Figueras-Aloy J, Miracle-Echegoyen X, Rodríguez-Miguélez JM, Salvia-Roiges MD, Carbonell-Estrany X. Trends in survival among extremely-low-birth-weight infants (less than 1000 g) without significant bronchopulmonary dysplasia. *BMC Pediatr.* 2012;12(1):63–70

10. Horbar JD, Carpenter JH, Badger GJ, et al. Mortality and neonatal morbidity among infants 501 to 1500 grams from 2000 to 2009. *Pediatrics.* 2012;129(6):1019–1026

11. Heldt G, McIlroy M. Distortion of chest wall and work of diaphragm in preterm infants. *J Appl Physiol (1985).* 1987;62(1):164–169

12. Heldt G, McIlroy M. Dynamics of chest wall in preterm infants. *J Appl Physiol (1985).* 1987;62(1):170–174

13. Barker PM, Gowen CW, Lawson EE, Knowles MR. Decreased sodium ion absorption across nasal epithelium of very premature infants with respiratory distress syndrome. *J Pediatr.* 1997;130(3):373–377

14. Obladen M. Factors influencing surfactant composition in the newborn infant. *Eur J Pediatr.* 1978;128(3):129–143

15. Dreyfuss D, Saumon G. Ventilator-induced lung injury: lessons from experimental studies. *Am J Respir Crit Care Med.* 1998;157(1):294–323

16. Mokres LM, Parai K, Hilgendorff A, et al. Prolonged mechanical ventilation with air induces apoptosis and causes failure of alveolar septation and angiogenesis in lungs of newborn mice. *Am J Physiol Lung Cell Mol Physiol.* 2010;298(1):L23–L35

17. Ambalavanan N, Van Meurs KP, Perritt R, et al; NICHD Neonatal Research Network, Bethesda, MD. Predictors of death or bronchopulmonary dysplasia in preterm infants with respiratory failure. *J Perinatol.* 2008;28(6):420–426

18. Van Marter LJ, Allred EN, Pagano M, et al. Do clinical markers of barotrauma and oxygen toxicity explain interhospital variation in rates of chronic lung disease? The Neonatology Committee for the Developmental Network. *Pediatrics.* 2000;105(6):1194–1201

19. Dunn MS, Kaempf J, de Klerk A, et al; Vermont Oxford Network DRM Study Group. Randomized trial comparing 3 approaches to the initial respiratory management of preterm neonates. *Pediatrics.* 2011;128(5):e1069–e1076

20. Morley CJ, Davis PG, Doyle LW, Brion LP, Hascoet J-M, Carlin JB; COIN Trial Investigators. Nasal CPAP or intubation at birth for very preterm infants. *N Engl J Med.* 2008;358(7):700–708

21. Finer NN, Carlo WA, Walsh MC, et al; SUPPORT Study Group of the Eunice Kennedy Shriver NICHD Neonatal Research Network. Early CPAP versus surfactant in extremely preterm infants. *N Engl J Med.* 2010;362(21):1970–1979

22. Fischer HS, Bührer C. Avoiding endotracheal ventilation to prevent bronchopulmonary dysplasia: a meta-analysis. *Pediatrics.* 2013;132(5):e1351–e1360

23. Schmölzer GM, Kumar M, Pichler G, Aziz K, O'Reilly M, Cheung P-Y. Non-invasive versus invasive respiratory support in preterm infants at birth: systematic review and meta-analysis. *BMJ.* 2013;347:f5980

24. Subramaniam P, Ho JJ, Davis PG. Prophylactic nasal continuous positive airway pressure for preventing morbidity and mortality in very preterm infants. *Cochrane Database Syst Rev.* 2016;6(6):CD001243

25. Committee on Fetus and Newborn; American Academy of Pediatrics. Respiratory support in preterm infants at birth. *Pediatrics.* 2014;133(1):171–174

26. Roberts CT, Hodgson KA. Nasal high flow treatment in preterm infants. *Matern Health Neonatol Perinatol.* 2017;3:15

27. Wilkinson D, Andersen C, O'Donnell CP, De Paoli AG, Manley BJ. High flow nasal cannula for respiratory support in preterm infants. *Cochrane Database Syst Rev.* 2016;2:CD006405

28. Lemyre B, Laughon M, Bose C, Davis PG. Early nasal intermittent positive pressure ventilation (NIPPV) versus early nasal continuous positive airway pressure (NCPAP) for preterm infants. *Cochrane Database Syst Rev.* 2016;12:CD005384

29. Lemyre B, Davis PG, De Paoli AG, Kirpalani H. Nasal intermittent positive pressure ventilation (NIPPV) versus nasal continuous positive airway pressure (NCPAP) for preterm neonates after extubation. *Cochrane Database Syst Rev.* 2017;2:CD003212

30. Björklund LJ, Ingimarsson J, Curstedt T, et al. Manual ventilation with a few large breaths at birth compromises the therapeutic effect of subsequent surfactant replacement in immature lambs. *Pediatr Res.* 1997;42(3):348–355

31. Klingenberg C, Wheeler KI, McCallion N, Morley CJ, Davis PG. Volume-targeted versus pressure-limited ventilation in neonates. *Cochrane Database Syst Rev.* 2017;10:CD003666

32. Cools F, Offringa M, Askie LM. Elective high frequency oscillatory ventilation versus conventional ventilation for acute pulmonary dysfunction in preterm infants. *Cochrane Database Syst Rev.* 2015;3(3):CD000104

33. Nkadi PO, Merritt TA, Pillers DA. An overview of pulmonary surfactant in the neonate: genetics, metabolism, and the role of surfactant in health and disease. *Mol Genet Metab.* 2009;97(2):95–101

34. Reynolds EO, Roberton NR, Wigglesworth JS. Hyaline membrane disease, respiratory distress, and surfactant deficiency. *Pediatrics.* 1968;42(5):758–768

35. Soll RF. Prophylactic natural surfactant extract for preventing morbidity and mortality in preterm infants. *Cochrane Database Syst Rev.* 2000;2(2):CD000511

36. Soll RF. Prophylactic synthetic surfactant for preventing morbidity and mortality in preterm infants. *Cochrane Database Syst Rev.* 2000;2(2):CD001079

37. Soll R, Ozek E. Prophylactic protein free synthetic surfactant for preventing morbidity and mortality in preterm infants. *Cochrane Database Syst Rev.* 2010;1(1):CD001079

38. Bahadue FL, Soll R. Early versus delayed selective surfactant treatment for neonatal respiratory distress syndrome. *Cochrane Database Syst Rev.* 2012;11:CD001456

39. Ardell S, Pfister RH, Soll R. Animal derived surfactant extract versus protein free synthetic surfactant for the prevention and treatment of respiratory distress syndrome. *Cochrane Database Syst Rev.* 2015;8:CD000144

40. Singh N, Halliday HL, Stevens TP, Suresh G, Soll R, Rojas-Reyes MX. Comparison of animal-derived surfactants for the prevention and treatment of respiratory distress syndrome in preterm infants. *Cochrane Database Syst Rev.* 2015;12(12):CD010249

41. Sinha SK, Lacaze-Masmonteil T, Valls i Soler A, et al; Surfaxin Therapy Against Respiratory Distress Syndrome Collaborative Group. A multicenter, randomized, controlled trial of lucinactant versus poractant alfa among very premature infants at high risk for respiratory distress syndrome. *Pediatrics.* 2005;115(4):1030–1038

42. Moya F, Sinha S, Gadzinowski J, et al; SELECT and STAR Study Investigators. One-year follow-up of very preterm infants who received lucinactant for prevention of respiratory distress syndrome: results from 2 multicenter randomized, controlled trials. *Pediatrics.* 2007;119(6):e1361–e1370

43. Victorin LH, Deverajan LV, Curstedt T, Robertson B. Surfactant replacement in spontaneously breathing babies with hyaline membrane disease--a pilot study. *Biol Neonate.* 1990;58(3):121–126

44. Stevens TP, Harrington EW, Blennow M, Soll RF. Early surfactant administration with brief ventilation vs. selective surfactant and continued mechanical ventilation for preterm infants with or at risk for respiratory distress syndrome. *Cochrane Database Syst Rev.* 2007;4(4):CD003063

45. Isayama T, Chai-Adisaksopha C, McDonald SD. Noninvasive ventilation with vs without early surfactant to prevent chronic lung disease in preterm infants: A systematic review and meta-analysis. *JAMA Pediatr.* 2015;169(8):731–739

46. More K, Sakhuja P, Shah PS. Minimally invasive surfactant administration in preterm infants: a meta-narrative review. *JAMA Pediatr.* 2014;168(10):901–908

47. Bao Y, Zhang G, Wu M, Ma L, Zhu J. A pilot study of less invasive surfactant administration in very preterm infants in a Chinese tertiary center. *BMC Pediatr.* 2015;15(1):21

48. Kanmaz HG, Erdeve O, Canpolat FE, Mutlu B, Dilmen U. Surfactant administration via thin catheter during spontaneous breathing: randomized controlled trial. *Pediatrics.* 2013;131(2):e502–e509

49. Kribs A, Roll C, Göpel W, et al; NINSAPP Trial Investigators. Nonintubated surfactant application vs conventional therapy in extremely preterm infants: A randomized clinical trial. *JAMA Pediatr.* 2015;169(8):723–730

50. Mirnia K, Heidarzadeh M, Hosseini MB, Sadeghnia A, Balila M, Ghojazadeh M. Comparison outcome of surfactant administration via tracheal catheterization during spontaneous breathing with INSURE. *Med J Islamic World Acad Sci.* 2013;21(4):143–148

51. Göpel W, Kribs A, Ziegler A, et al; German Neonatal Network. Avoidance of mechanical ventilation by surfactant treatment of spontaneously breathing preterm infants (AMV): an open-label, randomised, controlled trial. *Lancet.* 2011;378(9803):1627–1634

52. Foglia EE, Jensen EA, Kirpalani H. Delivery room interventions to prevent bronchopulmonary dysplasia in extremely preterm infants. *J Perinatol.* 2017;37(11):1171–1179

53. Isayama T, Iwami H, McDonald S, Beyene J. Association of noninvasive ventilation strategies with mortality and bronchopulmonary dysplasia among preterm infants: a systematic review and meta-analysis. *JAMA.* 2016;316(6):611–624

54. Dargaville PA, Kamlin CO, De Paoli AG, et al. The OPTIMIST-A trial: evaluation of minimally-invasive surfactant therapy in preterm infants 25-28 weeks gestation. *BMC Pediatr.* 2014;14:213

55. Doyle LW, Carse E, Adams AM, Ranganathan S, Opie G, Cheong JLY; Victorian Infant Collaborative Study Group. Ventilation in extremely preterm infants and respiratory function at 8 years. *N Engl J Med.* 2017;377(4):329–337

56. Jaffé A, Bush A. Anti-inflammatory effects of macrolides in lung disease. *Pediatr Pulmonol.* 2001;31(6):464–473

57. Aghai ZH, Kode A, Saslow JG, et al. Azithromycin suppresses activation of nuclear factor-kappa B and synthesis of pro-inflammatory cytokines in tracheal aspirate cells from premature infants. *Pediatr Res.* 2007;62(4):483–488

58. Wang EE, Ohlsson A, Kellner JD. Association of Ureaplasma urealyticum colonization with chronic lung disease of prematurity: results of a metaanalysis. *J Pediatr.* 1995;127(4):640–644

59. Schelonka RL, Katz B, Waites KB, Benjamin DK Jr. Critical appraisal of the role of Ureaplasma in the development of bronchopulmonary dysplasia with metaanalytic techniques. *Pediatr Infect Dis J.* 2005;24(12):1033–1039

60. Bose CL, Dammann CE, Laughon MM. Bronchopulmonary dysplasia and inflammatory biomarkers in the premature neonate. *Arch Dis Child Fetal Neonatal Ed.* 2008;93(6):F455–F461

61. Speer CP. Pulmonary inflammation and bronchopulmonary dysplasia. *J Perinatol.* 2006;26(suppl 1):S57–S62, discussion S63–S64

62. Nair V, Loganathan P, Soraisham AS. Azithromycin and other macrolides for prevention of bronchopulmonary dysplasia: a systematic review and meta-analysis. *Neonatology.* 2014;106 (4):337–347

63. Jensen EA, Foglia EE, Schmidt B. Evidence-based pharmacologic therapies for prevention of bronchopulmonary dysplasia: application of the Grading of Recommendations Assessment, Development, and Evaluation methodology. *Clin Perinatol.* 2015;42 (4):755–779

64. Ozdemir R, Erdeve O, Dizdar EA, et al. Clarithromycin in preventing bronchopulmonary dysplasia in *Ureaplasma urealyticum*-positive preterm infants. *Pediatrics.* 2011;128(6): e1496–e1501

65. Mabanta CG, Pryhuber GS, Weinberg GA, Phelps DL. Erythromycin for the prevention of chronic lung disease in intubated preterm infants at risk for, or colonized or infected with *Ureaplasma urealyticum. Cochrane Database Syst Rev.* 2003;4(4): CD003744

66. Schmidt B, Roberts RS, Davis P, et al; Caffeine for Apnea of Prematurity Trial Group. Caffeine therapy for apnea of prematurity. *N Engl J Med.* 2006;354(20):2112–2121

67. Schmidt B, Roberts RS, Davis P, et al; Caffeine for Apnea of Prematurity Trial Group. Long-term effects of caffeine therapy for apnea of prematurity. *N Engl J Med.* 2007;357 (19):1893–1902

68. Schmidt B, Roberts RS, Anderson PJ, et al; Caffeine for Apnea of Prematurity (CAP) Trial Group. Academic performance, motor function, and behavior 11 years after neonatal caffeine citrate therapy for apnea of prematurity: An 11-year follow-up of the CAP randomized clinical trial. *JAMA Pediatr.* 2017;171(6):564–572

69. Lodha A, Seshia M, McMillan DD, et al; Canadian Neonatal Network. Association of early caffeine administration and neonatal outcomes in very preterm neonates. *JAMA Pediatr.* 2015;169 (1):33–38

70. Patel RM, Leong T, Carlton DP, Vyas-Read S. Early caffeine therapy and clinical outcomes in extremely preterm infants. *J Perinatol.* 2013;33(2):134–140

71. Taha D, Kirkby S, Nawab U, et al. Early caffeine therapy for prevention of bronchopulmonary dysplasia in preterm infants. *J Matern Fetal Neonatal Med.* 2014;27(16):1698–1702

72. Davis PG, Schmidt B, Roberts RS, et al; Caffeine for Apnea of Prematurity Trial Group. Caffeine for Apnea of Prematurity trial: benefits may vary in subgroups. *J Pediatr.* 2010;156 (3):382–387

73. Dobson NR, Patel RM, Smith PB, Kuehn DR, Clark J, Vyas-Read S, et al. Trends in caffeine use and association between clinical outcomes and timing of therapy in very low birth weight infants. *J Pediatr.* 2014;164(5):992–998 e993

74. Niederreither K, Dollé P. Retinoic acid in development: towards an integrated view. *Nat Rev Genet.* 2008;9(7):541–553

75. Biesalski HK, Nohr D. Importance of vitamin-A for lung function and development. *Mol Aspects Med.* 2003;24(6):431–440

76. Shenai JP, Chytil F, Stahlman MT. Vitamin A status of neonates with bronchopulmonary dysplasia. *Pediatr Res.* 1985;19(2):185–188

77. Hustead VA, Gutcher GR, Anderson SA, Zachman RD. Relationship of vitamin A (retinol) status to lung disease in the preterm infant. *J Pediatr.* 1984;105(4):610–615

78. Chytil F. The lungs and vitamin A. *Am J Physiol.* 1992;262(5 Pt 1): L517–L527

79. Tyson JE, Wright LL, Oh W, et al; National Institute of Child Health and Human Development Neonatal Research Network. Vitamin A supplementation for extremely-low-birth-weight infants. *N Engl J Med.* 1999;340(25):1962–1968

80. Darlow BA, Graham PJ, Rojas-Reyes MX. Vitamin A supplementation to prevent mortality and short- and long-term morbidity in very low birth weight infants. *Cochrane Database Syst Rev.* 2016;8(8):CD000501

81. Gadhia MM, Cutter GR, Abman SH, Kinsella JP. Effects of early inhaled nitric oxide therapy and vitamin A supplementation on the risk for bronchopulmonary dysplasia in premature newborns with respiratory failure. *J Pediatr.* 2014;164(4):744–748

82. Tolia VN, Murthy K, McKinley PS, Bennett MM, Clark RH. The effect of the national shortage of vitamin A on death or chronic lung disease in extremely low-birth-weight infants. *JAMA Pediatr.* 2014;168(11):1039–1044

83. Meyer S, Gortner L; NeoVitaA Trial Investigators. Early postnatal additional high-dose oral vitamin A supplementation versus placebo for 28 days for preventing bronchopulmonary dysplasia or death in extremely low birth weight infants. *Neonatology.* 2014;105 (3):182–188

84. Doyle LW, Cheong JL, Ehrenkranz RA, Halliday HL. Early (< 8 days) systemic postnatal corticosteroids for prevention of bronchopulmonary dysplasia in preterm infants. *Cochrane Database Syst Rev.* 2017;10:CD001146

85. Doyle LW, Cheong JL, Ehrenkranz RA, Halliday HL. Late (> 7 days) systemic postnatal corticosteroids for prevention of bronchopulmonary dysplasia in preterm infants. *Cochrane Database Syst Rev.* 2017;10:CD001145

86. Onland W, van Kaam AH, De Jaegere AP, Offringa M. Open-label glucocorticoids modulate dexamethasone trial results in preterm infants. *Pediatrics.* 2010;126(4):e954–e964

87. Doyle LW, Halliday HL, Ehrenkranz RA, Davis PG, Sinclair JC. Impact of postnatal systemic corticosteroids on mortality and

cerebral palsy in preterm infants: effect modification by risk for chronic lung disease. *Pediatrics*. 2005;115(3):655–661

88. Doyle LW, Halliday HL, Ehrenkranz RA, Davis PG, Sinclair JC. An update on the impact of postnatal systemic corticosteroids on mortality and cerebral palsy in preterm infants: effect modification by risk of bronchopulmonary dysplasia. *J Pediatr*. 2014;165(6):1258–1260

89. Watterberg KL; American Academy of Pediatrics, Committee on Fetus and Newborn. Policy statement: postnatal corticosteroids to prevent or treat bronchopulmonary dysplasia. *Pediatrics*. 2010;126 (4):800–808

90. Doyle LW, Davis PG, Morley CJ, McPhee A, Carlin JB; DART Study Investigators. Low-dose dexamethasone facilitates extubation among chronically ventilator-dependent infants: a multicenter, international, randomized, controlled trial. *Pediatrics*. 2006;117 (1):75–83

91. Doyle LW, Davis PG, Morley CJ, McPhee A, Carlin JB; DART Study Investigators. Outcome at 2 years of age of infants from the DART study: a multicenter, international, randomized, controlled trial of low-dose dexamethasone. *Pediatrics*. 2007;119(4):716–721

92. Baud O, Maury L, Lebail F, et al; PREMILOC trial study group. Effect of early low-dose hydrocortisone on survival without bronchopulmonary dysplasia in extremely preterm infants (PREMILOC): a double-blind, placebo-controlled, multicentre, randomised trial. *Lancet*. 2016;387(10030):1827–1836

93. Baud O, Trousson C, Biran V, Leroy E, Mohamed D, Alberti C; PREMILOC Trial Group. Association between early low-dose hydrocortisone therapy in extremely preterm neonates and neurodevelopmental outcomes at 2 years of age. *JAMA*. 2017;317 (13):1329–1337

94. Shinwell ES, Portnov I, Meerpohl JJ, Karen T, Bassler D. Inhaled corticosteroids for bronchopulmonary dysplasia: A meta-analysis. *Pediatrics*. 2016;138(6):e20162511

95. Onland W, Offringa M, van Kaam A. Late (≥ 7 days) inhalation corticosteroids to reduce bronchopulmonary dysplasia in preterm infants. *Cochrane Database Syst Rev*. 2017;8:CD002311

96. Bassler D, Plavka R, Shinwell ES, et al; NEUROSIS Trial Group. Early inhaled budesonide for the prevention of bronchopulmonary dysplasia. *N Engl J Med*. 2015;373(16):1497–1506

97. Bassler D, Shinwell ES, Hallman M, et al; Neonatal European Study of Inhaled Steroids Trial Group. Long-term effects of inhaled budesonide for bronchopulmonary dysplasia. *N Engl J Med*. 2018;378(2):148–157

98. Venkataraman R, Kamaluddeen M, Hasan SU, Robertson HL, Lodha A. Intratracheal administration of budesonide-surfactant in prevention of bronchopulmonary dysplasia in very low birth weight infants: a systematic review and meta-analysis. *Pediatr Pulmonol*. 2017;52(7):968–975

99. Roberts D, Brown J, Medley N, Dalziel SR. Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. *Cochrane Database Syst Rev*. 2017;3:CD004454

100. Carlo WA, McDonald SA, Fanaroff AA, et al; Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network. Association of antenatal corticosteroids with mortality and neurodevelopmental outcomes among infants born at 22 to 25 weeks' gestation. *JAMA*. 2011;306 (21):2348–2358

101. Palta M, Gabbert D, Weinstein MR, Peters ME. Multivariate assessment of traditional risk factors for chronic lung disease in very low birth weight neonates. The Newborn Lung Project. *J Pediatr*. 1991;119(2):285–292

102. Oh W, Poindexter BB, Perritt R, et al; Neonatal Research Network. Association between fluid intake and weight loss during the first ten days of life and risk of bronchopulmonary dysplasia in extremely low birth weight infants. *J Pediatr*. 2005;147(6):786–790

103. Benitz WE. Patent ductus arteriosus: to treat or not to treat? *Arch Dis Child Fetal Neonatal Ed*. 2012;97(2):F80–F82

104. Fowlie PW, Davis PG, McGuire W. Prophylactic intravenous indomethacin for preventing mortality and morbidity in preterm infants. *Cochrane Database Syst Rev*. 2010; (7):CD000174

105. Ohlsson A, Walia R, Shah SS. Ibuprofen for the treatment of patent ductus arteriosus in preterm or low birth weight (or both) infants. *Cochrane Database Syst Rev*. 2018;9:CD003481

106. Ohlsson A, Shah PS. Paracetamol (acetaminophen) for patent ductus arteriosus in preterm or low birth weight infants. *Cochrane Database Syst Rev*. 2018;4:CD010061

107. Benitz WE; Committee on Fetus and Newborn, American Academy of Pediatrics. Patent ductus arteriosus in preterm infants. *Pediatrics*. 2016;137(1):e20153730

108. Clyman R, Cassady G, Kirklin JK, Collins M, Philips JB III. The role of patent ductus arteriosus ligation in bronchopulmonary dysplasia: reexamining a randomized controlled trial. *J Pediatr*. 2009;154(6):873–876

109. Kabra NS, Schmidt B, Roberts RS, Doyle LW, Papile L, Fanaroff A; Trial of Indomethacin Prophylaxis in Preterms Investigators. Neurosensory impairment after surgical closure of patent ductus arteriosus in extremely low birth weight infants: results from the Trial of Indomethacin Prophylaxis in Preterms. *J Pediatr*. 2007;150 (3):229–234, 234.e1

110. Kavvadia V, Greenough A, Dimitriou G, Hooper R. Randomised trial of fluid restriction in ventilated very low birthweight infants. *Arch Dis Child Fetal Neonatal Ed*. 2000;83(2):F91–F96

111. Iyengar A, Davis JM. Drug therapy for the prevention and treatment of bronchopulmonary dysplasia. *Front Pharmacol*. 2015;6:12

112. Barrington KJ, Finer N, Pennaforte T, Altit G. Nitric oxide for respiratory failure in infants born at or near term. *Cochrane Database Syst Rev*. 2017;1:CD000399

113. Askie LM, Ballard RA, Cutter GR, et al; Meta-analysis of Preterm Patients on Inhaled Nitric Oxide Collaboration. Inhaled nitric oxide in preterm infants: an individual-patient data meta-analysis of randomized trials. *Pediatrics*. 2011;128(4):729–739

114. Barrington KJ, Finer N, Pennaforte T. Inhaled nitric oxide for respiratory failure in preterm infants. *Cochrane Database Syst Rev*. 2017;1:CD000509

115. Askie LM, Davies LC, Schreiber MD, Hibbs AM, Ballard PL, Ballard RA. Race effects of inhaled nitric oxide in preterm infants: An individual participant data meta-analysis. *J Pediatr*. 2018;193:34–39.e2

116. Spiegler J, Preuß M, Gebauer C, Bendiks M, Herting E, Göpel W; German Neonatal Network (GNN); German Neonatal Network GNN. Does breastmilk influence the development of bronchopulmonary dysplasia? *J Pediatr*. 2016;169:76–80.e4

117. Hair AB, Peluso AM, Hawthorne KM, et al. Beyond necrotizing enterocolitis prevention: Improving outcomes with an exclusive human milk-based diet. *Breastfeed Med*. 2016;11(2):70–74

118. Villamor-Martínez E, Pierro M, Cavallaro G, Mosca F, Kramer BW, Villamor E. Donor human milk protects against bronchopulmonary dysplasia: A systematic review and meta-analysis. *Nutrients*. 2018;10(2):E238

NeoReviews Quiz

1. Bronchopulmonary dysplasia (BPD) is a common complication of prematurity and is associated with significant long-term morbidities including chronic respiratory and cardiovascular disorders, growth failure, and adverse neurodevelopmental outcomes. Ventilator-induced lung injury is an important factor contributing to the development of BPD and therefore the use of noninvasive respiratory support in very preterm infants has been extensively studied. Which of the following statements regarding the use of noninvasive positive airway pressure to prevent BPD is correct?

    A. Meta-analyses indicate an increased risk of pneumothorax with the use of early continuous positive airway pressure (CPAP) as initial mode of support.
    B. Meta-analyses indicate a small but significant reduction in the risk of death or BPD with early CPAP therapy.
    C. Heated and humidified high-flow nasal cannula has been shown to be equivalent to nasal CPAP for postextubation support.
    D. Nasal intermittent positive pressure ventilation (NIPPV) decreases BPD when used as the initial mode of respiratory support.
    E. Synchronized NIPPV has not been shown to be superior to asynchronous NIPPV with regard to BPD prevention.

2. Although noninvasive respiratory support is the preferred approach for most preterm infants, surfactant administration should be considered in preterm infants requiring intubation and mechanical ventilation. Which of the following statements regarding surfactant administration is correct?

    A. Surfactant administration after 1 hour of age does not reduce the risk for BPD.
    B. Lucinactant, a synthetic surfactant containing a peptide analog of protein B, has a lower efficacy than animal-derived surfactants.
    C. The INSURE (*in*tubation, *sur*factant administration during brief mechanical ventilation, followed by *ex*tubation) technique has been shown to decrease the risk for BPD compared with CPAP alone.
    D. Less invasive surfactant administration techniques reduce BPD risk among survivors compared with control therapies.
    E. In a recent Bayesian network meta-analysis, nebulized surfactant administered via laryngeal mask airway was associated with the largest reduction in the risk for death or BPD.

3. BPD is multifactorial and strategies for prevention must include multiple evidence-based practices. Which of the following statements regarding pharmacologic measures to prevent BPD in preterm infants is FALSE?

    A. Azithromycin reduces the risk for death or BPD in preterm infants colonized or infected with *Ureaplasma*.
    B. Caffeine decreases the risk for BPD in preterm infants with birthweights of 500 to 1,250 g.
    C. Intramuscular injections of vitamin A for 4 weeks after birth has been shown to decrease BPD in extremely low-birthweight infant survivors.
    D. In the PREMILOC trial, hydrocortisone within the first 24 hours after birth was associated with an increased risk of late-onset sepsis in infants born at 24 to 25 weeks.
    E. In the multicenter NEUROSIS trial, inhaled budesonide reduced the risk for BPD in survivors but was associated with increased mortality.

4. Corticosteroids are attractive therapeutic agents for BPD prevention because of their potent anti-inflammatory properties. Among corticosteroid agents, dexamethasone has been the most studied. Which of the following statements regarding the use of dexamethasone to decrease BPD is correct?

   A. Early dexamethasone is defined as treatment initiation within 14 days of birth.
   B. Early dexamethasone treatment is associated with increased risk of gastrointestinal perforation and hypertrophic cardiomyopathy, but not cerebral palsy.
   C. In a meta-analysis of late dexamethasone use, the risk for cerebral palsy was found to be significantly increased in dexamethasone-treated infants.
   D. Based on a meta-regression study by Doyle et al, late dexamethasone should be considered in infants in whom the risk for BPD exceeds 80%.
   E. In the Dexamethasone: A Randomized Trial (DART) study, low-dose dexamethasone did not result in lower BPD risk.

5. In very preterm infants in the NICU, BPD has remained a challenging morbidity to prevent and treat. Which of the following interventions or practices in neonatal care has been associated with lower BPD risk either in controlled trials or consistently in observational studies?

   A. Donor human milk.
   B. Inhaled nitric oxide in early preventive strategies, but only for non-black patients.
   C. Higher fluid intake during the first week after birth.
   D. Indomethacin prophylaxis or treatment for patent ductus arteriosus within the first week after birth.
   E. Low-dose hydrocortisone initiated soon after birth for a 10-day course.

Prevention of Bronchopulmonary Dysplasia: A Summary of Evidence-Based Strategies

Erik A. Jensen

Updated Information & Services	including high resolution figures, can be found at: http://neoreviews.aappublications.org/content/20/4/e189
References	This article cites 117 articles, 25 of which you can access for free at: http://neoreviews.aappublications.org/content/20/4/e189.full#ref-list-1
Subspecialty Collections	This article, along with others on similar topics, appears in the following collection(s): **Pediatric Drug Labeling Update** http://classic.neoreviews.aappublications.org/cgi/collection/pediatric_drug_labeling_update
Permissions & Licensing	Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at: https://shop.aap.org/licensing-permissions/
Reprints	Information about ordering reprints can be found online: http://classic.neoreviews.aappublications.org/content/reprints

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://neoreviews.aappublications.org/content/20/4/e189

American Academy of Pediatrics
DEDICATED TO THE HEALTH OF ALL CHILDREN®